Form 4: Enliven Therapeutics CSO Sells Shares

Sentiment:

Insider Transaction Report 21 August 2025 6:46 PM

📋All filings for Enliven Therapeutics, INC

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 12,500 shares of common stock in August 2025 under a pre-arranged trading plan.

Worse than expectedThe Chief Scientific Officer sold a significant number of shares, which can be interpreted by the market as a lack of confidence or a belief that the stock is fully valued, despite being executed under a 10b5-1 plan.

Summary

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported sales of common stock.
On August 19, 2025, 5,000 shares were sold at a weighted average price of $19.6235 per share.
On August 21, 2025, an additional 7,500 shares were sold at a weighted average price of $20.0132 per share.
These sales were executed under a Rule 10b5-1 trading plan established on November 15, 2024.
Following these transactions, Lyssikatos beneficially owns 940,188 shares of common stock, held indirectly through The Lyssikatos Revocable Trust.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive, even under a pre-arranged plan, can be viewed negatively by investors as it reduces insider ownership and may signal a belief that the stock is adequately valued or that the executive needs liquidity.

Positives

The sales were conducted under a Rule 10b5-1 trading plan, adopted on November 15, 2024, indicating pre-planned transactions and adherence to insider trading regulations.

Negatives

Chief Scientific Officer Joseph P. Lyssikatos sold a total of 12,500 shares of common stock, which reduces insider ownership.
The sales occurred at prices ranging from $19.0925 to $20.11, potentially indicating the executive's view that the stock price is at a favorable level for liquidity purposes.

Risks

Potential negative market perception due to insider selling, even if pre-planned, which could lead to short-term downward pressure on the stock price.
Reduced alignment of interests between the Chief Scientific Officer and common shareholders due to decreased equity holdings.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders may interpret the insider sale as a signal regarding the executive's view on the company's future prospects or valuation.

Key Dates

Date	Description
11/15/2024	Date Rule 10b5-1 trading plan was adopted by Joseph P. Lyssikatos.
08/19/2025	Date of sale of 5,000 shares of common stock by Joseph P. Lyssikatos.
08/21/2025	Date of sale of 7,500 shares of common stock by Joseph P. Lyssikatos and filing date of Form 4.

Recommendation

hold

While the sale by the Chief Scientific Officer could be perceived negatively, it was executed under a pre-arranged 10b5-1 trading plan, which suggests the decision to sell was made in advance and not based on immediate, non-public information. This mitigates the negative signal somewhat. Without additional company-specific news or broader market context, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient grounds for a strong buy or sell decision, but warrants monitoring for further insider activity or company developments.

Keywords

Enliven Therapeutics, ELVN, insider trading, Form 4, stock sale, Joseph Lyssikatos, Chief Scientific Officer, 10b5-1 plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.